GLPwatch
Initiating Titratable Fixed-Ratio Combinations of Basal Insulin Analogs and Glucagon-Like Peptide-1 Receptor Agonists: What You Need to Know.
Clin Diabetes · 2018
Last updated 2026-05-28Two approved medications combine basal insulin with a GLP-1 receptor agonist in a single dose: insulin degludec/liraglutide and insulin glargine/lixisenatide. These combinations aim to lower blood sugar while reducing side effects like low blood sugar or weight gain from insulin and stomach issues from GLP-1 drugs.
AI summary of the abstract below.
| Journal | Clin Diabetes, 2018 |
|---|---|
| Citations | 5 |
| Relative citation ratio | 0.26 |
| NIH percentile | 16 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes |
Abstract
Titratable fixed-ratio combinations (FRCs) of a basal insulin and a glucagon-like peptide-1 (GLP-1) receptor agonist are new therapeutic options for people with type 2 diabetes. Two FRCs-insulin degludec/liraglutide and insulin glargine/lixisenatide-have been approved for use in the United States. The two components in these FRCs target different aspects of diabetes pathophysiology, working in a complementary manner to decrease blood glucose while mitigating the side effects associated with each component (hypoglycemia and weight gain with insulin and gastrointestinal side effects with GLP-1 receptor agonists). This article reviews these products and key considerations for their use.
Verbatim abstract via PubMed 29686457 ↗